Physician profile
Mark Antosh
NPI 1295746584
$3,284.91
in general payments reported to CMS, 2019-2025
17 companies · $240 in 2025
The $240 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $568 · 2021: $500 · 2022: $773 · 2023: $574 · 2024: $299 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,113.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,683.58 | 2019-2025 | Liletta, Lo Loestrin Fe |
| Therapeuticsmd, INC. | $419.98 | 2019-2022 | |
| Pfizer INC. | $276.61 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $182.77 | 2021-2025 | |
| Astellas Pharma US INC | $162.27 | 2024-2025 | Veozah |
| Minerva Surgical, INC | $108.48 | 2020 | |
| Allergan, INC. | $76.28 | 2019-2020 | |
| Avion Pharmaceuticals | $75.69 | 2021-2022 | |
| Coopersurgical, INC. | $68.69 | 2020-2022 | |
| Mylan Pharmaceuticals INC. | $44.13 | 2021-2022 | |
| Lupin INC. | $39.37 | 2020 | |
| Millicent US INC | $39.03 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Merck Sharp & Dohme LLC | $37.05 | 2020-2023 | Gardasil 9 |
| Axonics, INC. | $27.69 | 2024 | Bulkamid |
| Exact Sciences Corporation | $14.57 | 2024 | Cologuard Collection Kit |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Virtus Pharmaceuticals LLC | $14.38 | 2022 | |
| Scynexis, INC. | $14.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Antosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.